You are here

Article Text

Article menu
Download PDFPDF
Original article
ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas
  1. Wen-Chiuan Tsai1,2,
  2. Dueng-Yuan Hueng3,
  3. Shin Nieh1,
  4. Hong-Wei Gao1
  1. 1Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
  2. 2Graduate Institute of Engineering Technology, College of Engineering, National Taipei University of Technology, Taipei, Taiwan
  3. 3Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
  1. Correspondence to Dr Wen-Chiuan Tsai, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu, Taipei 114, Taiwan; drtsaiwenchuan{at}mail2000.com.tw

Abstract

Aims Although ARID4B is known to promote tumour metastasis in breast cancer and inhibit transformation and progression in leukaemia, the possible effect of ARID4B on primary brain tumours (PBTs) is not well characterised. We tested the hypothesis that expression of ARID4B correlates with WHO grade and survival in patients with PBTs.

Methods Western blot analysis was performed on protein lysates prepared from normal brain tissue and glioma cell lines (U87MG, LN229, GBM8401 and U118MG). Subsequently, immunohistochemical analysis of ARID4B was performed on 2 tissue microarrays, including 12 normal brain tissues, 63 meningiomas with different subtypes, 232 gliomas of various grades and degrees of differentiation, 8 central neurocytomas and 4 chordomas. The ARID4B immunostaining score was calculated by multiplying the intensity score by the percentage of tumour cells expressing ARID4B.

Results In vitro, ARID4B protein expression was increased in some glioma cell lines. In addition, the average ARID4B immunostaining score was 38.03, 79.09, 129.76 and 119.32, respectively, in gliomas of WHO grade I, II, III and IV. Higher ARID4B immunostaining score was significantly correlated with more advanced WHO grade of gliomas (p=7.4×10–6) and meningiomas. Finally, higher ARID4B expression tended to the shorter survival rates, but did not reach statistical significance.

Conclusions ARID4B overexpression presented in most of PBTs, rather than non-neoplastic brain tissue, and correlated with WHO grades in meningiomas and gliomas. Therefore, ARID4B is a satisfactory biomarker to highlight tumour component and predict tumour behaviour in primary brain neoplasms.

  • BRAIN TUMOURS
  • IMMUNOHISTOCHEMISTRY
  • SURGICAL PATHOLOGY

https://doi.org/10.1136/jclinpath-2016-203804

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Cheok Soon Lee

    • Contributors W-CT: perform western blot analysis and response to complete manuscript written and submission. W-CT, H-WG, SN: response to evaluate IHC scores. D-YH: response to supply cases and prepare IRB approved.

    • Funding This study was supported by grants from the Tri-Service General Hospital, TSGH-C102-073, TSGH-C104-075, TSGH-C105-073, and National Defense Medical Center, MAB-105-098, Taiwan, R.O.C.

    • Competing interests None declared.

    • Ethics approval Tri-Service General Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.